Scopio Labs

Company Overview

Snapshot

Founded in October 2014 by Itai Hayut and Erez Na'aman, Scopio Labs operates with 51–200 employees. The company has raised over $126.76 million across 9 funding rounds from 13 investors. In July 2024, Scopio Labs secured a Series D funding round with.

Business overview

Scopio Labs develops a proprietary diagnostics platform centered on computational microscopy to enhance the quality and accessibility of microscopic analysis. The company merges advanced hardware and software, including AI-powered decision support systems, to automate and streamline the screening process for blood diagnostics. Serving the healthcare industry, particularly clinics, hospitals, and laboratories, Scopio Labs' technology aims to improve efficiency, reduce human error, and provide comprehensive digital imaging solutions for various applications, including peripheral blood smears and bone marrow aspirates.

Strategic signal

In January 2025, Scopio Labs expanded its strategic alliance with Siemens Healthineers to include the global distribution of its digital bone marrow aspirate solution. This development signifies a major validation of Scopio Labs' technology and market reach, indicating a strong trajectory for broader adoption of its AI-powered diagnostic platforms within the global healthcare market.

Company Intelligence Q&A

What is Scopio Labs' core technology?

Scopio Labs has developed a computational microscope and a proprietary diagnostics platform that integrates hardware and software to provide quality microscopic analysis, automating screening processes and leveraging AI for decision support.

Which major regulatory milestone did Scopio Labs achieve in February 2026?

In February 2026, Scopio Labs achieved IVDR certification from BSI for its AI-powered Full-Field digital morphology platforms, clearing the path for its solutions in the EU market.

What was a significant partnership announcement for Scopio Labs in January 2025?

In January 2025, Scopio Labs announced an extension of its strategic alliance with Siemens Healthineers to include the global distribution of Scopio's digital bone marrow aspirate solution.

What was the outcome of the Series D funding round in July 2024?

In July 2024, Scopio Labs secured a Series D funding round, with.

When did Scopio Labs receive FDA clearance for its high-throughput hematology digital cell morphology platform?

In June 2022, Scopio Labs was awarded FDA clearance for its high-throughput hematology digital cell morphology platform, designed to replace traditional microscopes with digitization.